New eczema drug CM512 enters first human safety trial

NCT ID NCT06553209

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new drug called CM512 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the body handles the drug. 110 participants will receive either CM512 or a placebo, and researchers will monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CM512 injection

What this could lead to

If successful, this could lead to a new treatment option for people with moderate to severe atopic dermatitis.

What could go wrong

This is an early Phase 1 trial focused on safety, so it is too soon to know if CM512 will work. The study is small and may not show clear benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China